Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21925724 | 0.81 | TP53 (0.49) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL23795275 | 0.81 | TP53 (0.49) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL23795255 | 0.81 | MDM2 (0.43) | SMN1; SMN2MAPK1 | |
| SCHEMBL23795303 | 0.78 | TP53 (0.43) | SMN1; SMN2TP53THRBMAPTKMT2A | |
| SCHEMBL21925726 | 0.76 | APP (0.33) | — | |
| SCHEMBL21925717 | 0.76 | FSHR (0.41) | SMN1; SMN2MAPTKMT2A | |
| SCHEMBL30928801 | 0.76 | FSHR (0.41) | SMN1; SMN2MAPTKMT2A | |
| SCHEMBL23795250 | 0.76 | TP53 (0.52) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL23795274 | 0.75 | MDM2 (0.43) | SMN1; SMN2MAPK1 | |
| SCHEMBL23795261 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2TP53CCR2THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | DOTTIKON ES HOLDING AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877357-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3650438-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2020-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | NR0B2, KCNJ2, TRRAP | SMN1; SMN2 3918/4885TP53 3228/4885HTR2A 361/4885 |
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | NR0B2, KCNJ2, TRRAP | SMN1; SMN2 3918/4885TP53 3228/4885HTR2A 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.